Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of GC1107 Td Vaccine in Healthy Adults
NCT02361866Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- May 2014
- Primary completion
- Sep 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegteograstim in diphtheria and Tetanus (2 arms), sponsored by GC Biopharma. Primary endpoint: seroprotection rate of diphtheria and tetanus at 28 days. Started May 2014; status: completed.
02
Drugs
pegteograstim
03
Conditions
diphtheriaTetanus
Beyond the preview
Go deeper on NCT02361866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361866.